Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 56 publications
DPP9-mediated inflammasome repression protects against checkpoint inhibitor lung toxicity.
Journal: bioRxiv : the preprint server for biology
Published: July 11, 2026
Correction: Metabolic syndrome and immune-related adverse events.
Journal: Cancer immunology, immunotherapy : CII
Published: May 14, 2026
A new therapeutic approach to KRAS mutant non-small cell lung cancer: the emerging role of exportin 1 inhibition.
Journal: Translational lung cancer research
Published: December 28, 2025
Predictive Biomarkers for Immune Checkpoint Inhibitor Efficacy: Challenges, Innovations, and a Pathway to Precision Medicine in the Era of Cancer Immunotherapy.
Journal: Clinical chemistry
Published: November 21, 2025
Deciphering small sequence differences in T cell receptor-antigen pairing.
Journal: Nature communications
Published: November 05, 2025
Nipah and Hendra Viruses Use an Adjustable Latch in Receptor Engagement.
Journal: ACS infectious diseases
Published: September 26, 2025
Genetic haplotypes in VWA8, OSBPL6, and ADAMTS9-AS2 are associated with immune-related adverse effects in ICI-treated patients with cancer.
Journal: Journal for immunotherapy of cancer
Published: September 22, 2025
Innate and adaptive immune features associated with immune-related adverse events.
Journal: Journal for immunotherapy of cancer
Published: July 30, 2025
Immune Checkpoint Inhibitor Outcomes in NSCLC Across Populations and Practice Settings.
Journal: JTO clinical and research reports
Published: July 22, 2025
Metabolic syndrome and immune-related adverse events.
Journal: Cancer immunology, immunotherapy : CII
Published: July 17, 2025
Association of PD-L1 expression with systemic immune parameters in non-small cell lung cancer.
Journal: Translational lung cancer research
Published: April 10, 2025
Last Updated: 09/26/2026